Table 2.
Baseline characteristics of patients included in final analysis
| Characteristic | All patients (n = 207) | Wildtype CYP3A4 patients (n = 173) | CYP3A4*22 carriers (n = 34) |
|---|---|---|---|
| Sex | |||
| Female | 95 (46%) | 75 (43%) | 20 (59%) |
| Male | 112 (54%) | 98 (57%) | 14 (41%) |
| Ethnic origin | |||
| White | 188 (91%) | 155 (90%) | 33 (97%) |
| Asian | 6 (3%) | 6 (3%) | – |
| Arabic | 6 (3%) | 6 (3%) | – |
| Black | 3 (2%) | 3 (2%) | – |
| Other | 4 (2%)a | 3 (2%)b | 1 (3%)c |
| Age (at inclusion) | |||
| Median [IQR] in years | 64 [55–73] | 65 [56–73] | 62 [55–72] |
| WHO performance score | |||
| 0 | 96 (46%) | 79 (46%) | 17 (50%) |
| 1 | 89 (43%) | 75 (43%) | 14 (41%) |
| 2 | 22 (11%) | 19 (11%) | 3 (9%) |
| CYP3A4*22 status | |||
| No CYP3A4 *22 carrier | 173 (84%) | 173 (100%) | NA |
| Heterozygote CYP3A4 *22 carrier | 31 (15%) | NA | 31 (91%) |
| Homozygote CYP3A4 *22 carrier | 3 (1%) | NA | 3 (9%) |
| Other CYP3A4 SNPs | |||
| CYP3A4 *1/*1B | 14 (6.8%) | 14 (8%) | – |
| CYP3A4 *1B/*1B | 1 (0.5%) | 1 (0.6%) | – |
| CYP3A4 *1/*3 | 1 (0.5%) | 1 (0.6%) | – |
| CYP3A4 *1/*12 | 1 (0.5%) | 1 (0.6%) | – |
| CYP3A4 *3/*22 | 5 (2.4%) | NA | 5 (15%) |
| No other SNPs | 185 (89%) | 156 (90%) | 29 (85%) |
| Drug | |||
| Cabozantinib | 9 (4%) | 6 (4%) | 3 (9%) |
| Dabrafenib | 30 (15%) | 26 (15%) | 4 (12%) |
| Imatinib (400 mg starting dose only) | 76 (37%) | 66 (38%) | 10 (29%) |
| Osimertinib | 21 (10%) | 18 (10%) | 3 (9%) |
| Pazopanib | 46 (22%) | 35 (20%) | 11 (32%) |
| Sunitinib | 25 (12%) | 22 (13%) | 3 (9%) |
| Primary malignancy | |||
| GIST | 85 (41%) | 75 (43%) | 10 (29%) |
| Sarcoma | 46 (22%) | 35 (20%) | 11 (32%) |
| Melanoma | 26 (13%) | 23 (13%) | 3 (9%) |
| Lung cancer | 25 (12%) | 21 (12%) | 4 (12%) |
| Renal cell carcinoma | 24 (12%) | 18 (10%) | 6 (18%) |
| Neuroendocrine tumor | 1 (1%) | 1 (1%) | 0 (0%) |
| Metastatic disease | |||
| Yes | 148 (71%) | 125 (72%) | 23 (68%) |
| No | 59 (29%) | 48 (28%) | 11 (32%) |
| Prior systemic treatment | |||
| Yes | 87 (42%) | 71 (41%) | 16 (47%) |
| No | 120 (58%) | 102 (59%) | 18 (53%) |
GIST gastro-intestinal stromal tumor, IQR interquartile range, NA not applicable, SNP single nucleotide polymorphism, WHO World Health Organization
aMixed racial parentage (n = 2), latino (n = 1), unknown ethnic origin (n = 1)
bMixed racial parentage (n = 1), latino (n = 1), unknown ethnic origin (n = 1)
cMixed racial parentage (n = 1)